Welcome to our dedicated page for Prenetics SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prenetics Global Limited filings document a foreign private issuer that furnishes Form 6-K reports for material corporate updates, financial results and press-release exhibits. The filings cover the company’s IM8 consumer health and longevity business, including product and partnership announcements, operating results, registration-statement incorporation and disclosures tied to its focus on global expansion of the brand.
The filing record also documents capital allocation and governance matters, including Class A Ordinary Share repurchase authorization, executive open-market share purchases, board changes, treasury policy related to digital assets and completed divestiture activity such as the sale of the company’s Insighta equity interest. These disclosures frame Prenetics’ capital structure, liquidity commentary and reported business priorities as a public foreign issuer.
Prenetics Global Limited announced a multi-year global partnership with NBA champion and two-time MVP Giannis Antetokounmpo, who becomes a global partner of IM8 and a shareholder in Prenetics. This aligns his 35 million-plus social followers with IM8’s growth strategy across the United States, Europe, Africa, and Asia.
IM8, co-founded with David Beckham, has rapidly scaled since its December 2024 launch, reaching $100 million in annualized recurring revenue in 11 months, more than 22 million servings delivered and about 750,000 customer purchases in 31 countries. The brand is projected to generate approximately $180–$200 million in revenue in 2026.
Management highlights strong alignment with athlete-partners, all of whom hold equity, and notes up to $42.75 million in combined corporate and personal share commitments. Prenetics reports approximately $160 million of adjusted liquidity and zero debt as of March 1, 2026, with adjusted EBITDA profitability targeted by Q4 2027.
Prenetics Global Limited registers for resale 2,360,416 Class A Ordinary Shares issuable upon exercise of Exchange Warrants. The resale registration covers shares held by selling shareholders and the company will not receive proceeds from resale, although it may receive proceeds if the Exchange Warrants are exercised for cash. Shares outstanding were 14,697,463 Class A Ordinary Shares as of March 31, 2026.
The Exchange Warrants were issued in connection with prior warrant exchanges and become exercisable upon effectiveness of this registration statement; each warrant has an $18.00 exercise price and a two-year term from first exercisability.
Prenetics Global Ltd director Darshan Ravindra Shah filed an initial ownership statement showing equity interests in the company. He holds 5,599 Restricted Stock Units, each representing a right to receive one Class A Ordinary Share, which vest on February 15, 2027 under the 2022 Share Incentive Plan.
Following this filing, he also holds 4,506 Class A Ordinary Shares directly. The RSUs are scheduled to be settled and delivered in shares upon vesting, with the award expiring on February 16, 2032.
Prenetics Global Ltd director and Chief Executive Officer Danny Sheng Wu Yeung has reported his initial ownership on a Form 3. He directly holds 933,380 Class B Ordinary Shares and 138,694 Class A Ordinary Shares. He also has indirect ownership of 647,592 Class B Ordinary Shares through Da Yeung Limited, a company he wholly owns.
Yeung additionally holds Restricted Stock Units representing 53,953 underlying Class B Ordinary Shares at an exercise price of $0.0001 per share, expiring on June 23, 2030. These RSUs were granted under the 2022 Share Incentive Plan and vest in scheduled tranches during 2026, with settlement of vested RSUs in Ordinary or Class A shares at his election.
Prenetics Global Ltd director Cheng Yin Pan filed an initial ownership report showing indirect holdings through M13 Capital Management Holdings Limited. The filing lists 75,021 Class A Ordinary Shares and 15,873 Restricted Stock Units, each RSU representing one Class A Ordinary Share vesting on May 17, 2026.
Prenetics Global Ltd Chief Financial Officer Hoi Chun Lo reported his initial equity holdings. He directly owns 487,462 Class A Ordinary Shares and two groups of Restricted Stock Units that can convert into 15,272 and 32,736 Class A Ordinary Shares at nominal exercise prices, with vesting in 2026 and expirations in 2030 and 2032.
Prenetics Global Ltd director David Vanderveen filed an initial ownership report showing his equity holdings. He directly holds 38,305 Class A Ordinary Shares and an additional 1,648 Class A Ordinary Shares are held indirectly by his spouse. He also holds 8,681 Restricted Stock Units granted under the 2022 Share Incentive Plan, each representing one Class A Ordinary Share. These RSUs vest on June 15, 2026, subject to continued service, and will be settled in shares upon vesting.
Prenetics Global Limited announced that its Board of Directors has authorized a share repurchase program of up to $40 million of its Class A Ordinary Shares over a 12‑month period. This follows open‑market purchases by executives totaling approximately $2.75 million of personal capital across recent post‑earnings trading windows.
The company reports approximately $164 million in total adjusted liquidity as of March 1, 2026 and zero debt, supported by cash, fixed‑income funds, digital assets and divestiture proceeds. Its IM8 brand is targeting $180 million to $200 million in 2026 full‑year revenue and adjusted EBITDA profitability by Q4 2027, and the buyback may be executed via open‑market, block or negotiated purchases, including under Rule 10b5‑1 trading plans.
Prenetics Global Limited reported that its executive leadership team completed a second round of open market purchases of Prenetics common stock during the week of February 23–27, 2026, following the release of its 2025 year-end results. Executives acquired 76,060 shares for an aggregate of about $1,301,000, at an average price of roughly $17.11 per share.
CEO Danny Yeung bought 42,282 shares for approximately $750,000, CFO Stephen Lo bought 15,603 shares for about $250,000, CMO Rahul Ramchand bought 15,000 shares for about $251,000, and President of Americas David Vanderveen bought 3,175 shares for about $50,000. Together with a prior round after the November 2025 earnings release, leadership has now personally invested roughly $2.75 million in Prenetics shares.
The company highlights the growth of its IM8 consumer health brand, which surpassed $100 million in annualized recurring revenue within 11 months and is sold in more than 30 countries.
Prenetics Global Limited reported record 2025 results driven by its IM8 consumer health brand. Full-year revenue jumped to $92.4 million, up 479.7% year over year, with fourth-quarter revenue at $36.6 million, a 457.1% increase, as IM8 became the main growth engine.
IM8 delivered $60.1 million of 2025 revenue and reached about $120 million in annualized recurring revenue by December 2025, with December monthly revenue at $10.0 million and gross margin near 60%. Company-wide adjusted EBITDA loss narrowed to $13.0 million for 2025 and $2.3 million in Q4, showing improving operating leverage despite heavy marketing spend.
Prenetics completed divestitures of ACT Genomics, Europa and its 35% Insighta stake, lifting total adjusted liquidity to $171.1 million as of February 15, 2026, with no debt. Management reaffirmed 2026 IM8 revenue guidance of $180–$200 million and outlined a path toward adjusted EBITDA profitability by the fourth quarter of 2027.
Prenetics Global Limited reported record 2025 results driven by its IM8 consumer health brand. Full-year revenue jumped to $92.4 million, up 479.7% year over year, with fourth-quarter revenue at $36.6 million, a 457.1% increase, as IM8 became the main growth engine.
IM8 delivered $60.1 million of 2025 revenue and reached about $120 million in annualized recurring revenue by December 2025, with December monthly revenue at $10.0 million and gross margin near 60%. Company-wide adjusted EBITDA loss narrowed to $13.0 million for 2025 and $2.3 million in Q4, showing improving operating leverage despite heavy marketing spend.
Prenetics completed divestitures of ACT Genomics, Europa and its 35% Insighta stake, lifting total adjusted liquidity to $171.1 million as of February 15, 2026, with no debt. Management reaffirmed 2026 IM8 revenue guidance of $180–$200 million and outlined a path toward adjusted EBITDA profitability by the fourth quarter of 2027.